Overview
- Anthropic said Wednesday it appointed Novartis chief Vas Narasimhan to its board, resulting in a majority for directors chosen by its Long‑Term Benefit Trust.
- Narasimhan is a physician‑scientist who has led Novartis since 2018 and overseen approvals for more than 35 medicines and vaccines.
- Anthropic is a public‑benefit company that uses the Long‑Term Benefit Trust to anchor mission‑focused oversight, with the new majority strengthening that control.
- The choice aligns with a push into healthcare uses of AI, including work with Eli Lilly, Novo Nordisk and Genmab on drug discovery.
- Investors read the board changes as preparation for a possible IPO, with Chris Liddell’s addition earlier this year part of the same effort, though no listing plan is announced.